By writer to www.biospace.com
SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a number one precision drugs firm centered on the invention, improvement, and commercialization of clinically differentiated, high-value healthcare options for transplant sufferers and caregivers, pronounces right now that the journal of the American Society of Nephrology, Kidney360, revealed a examine evaluating AlloSure concurrently with a distinct donor-derived cell-free DNA (dd-cfDNA) monitoring instrument for allograft rejection.
This examine evaluated 76 kidney transplant sufferers and surveilled post-transplant kidney rejection using AlloSure and one different dd-cfDNA monitoring instrument. General, the examine discovered that whereas there have been no vital variations between the diagnostic check traits, AlloSure was confirmed to be extra correct in scientific interpretation and considerably sooner in delivering affected person outcomes. The examine evaluated dd-cfDNA samples and concluded that AlloSure had a considerably superior turnaround time with 75% of the outcomes returned a minimum of in the future earlier.
“Our examine findings additional validated the revealed information on AlloSure, a transplant-focused analytical instrument for allograft rejection utilizing donor-derived cell-free DNA,” mentioned Joseph Ok. Melancon, MD, The George Washington College Hospital. “Though dd-cfDNA checks are related, they don’t seem to be the identical.”
“Whereas CareDx was not concerned on this head-to-head comparability, we’re not stunned by the outcomes as AlloSure was developed for transplant particular wants, together with correct testing at low cfDNA ranges and quick turnaround instances,” mentioned Sham Dholakia, SVP of Medical Affairs at CareDx.
CareDx, Inc., headquartered in South San Francisco, California, is a number one precision drugs options firm centered on the invention, improvement and commercialization of clinically differentiated, high-value healthcare options for transplant sufferers and caregivers. CareDx provides testing providers, merchandise, and digital healthcare options alongside the pre- and post-transplant affected person journey, and is the main supplier of genomics-based info for transplant sufferers. For extra info, please go to: www.CareDx.com.
Chief Advertising Officer
— to www.biospace.com